COVID-19 vaccine effectiveness in adults with developmental disabilities living in group homes

Hirsch, Karyn; Reidenberg, Bruce E.

doi:10.1016/j.puhe.2022.05.006

Public Health

2022

DOI: 10.1016/j.puhe.2022.05.006

|View full text |Cite

COVID-19 vaccine effectiveness in adults with developmental disabilities living in group homes

Karyn Hirsch¹,

Bruce E. Reidenberg²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“They need to speak a language everyone can understand”: Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities

Campanella,

Volpe,

Safar

et al. 2025

Vaccine

View full text Add to dashboard Cite

“They need to speak a language everyone can understand”: Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities

Campanella,

Volpe,

Safar

et al. 2025

Vaccine

View full text Add to dashboard Cite

COVID-19 vaccine effectiveness and uptake in a national cohort of English children and young people with life-limiting neurodisability

Cruz,

Harwood,

Kenny

et al. 2024

Arch Dis Child

View full text Add to dashboard Cite

ObjectiveTo investigate SARS-CoV-2 vaccine uptake and effectiveness in children and young people (CYP) with life-limiting neurodisability.DesignWe undertook a retrospective cohort study using national hospital data in England from 21 December 2020 to 2 September 2022 to describe SARS-CoV-2 vaccination uptake, and then examined COVID-19 hospitalisation, paediatric intensive care unit (PICU) admission and death following SARS-CoV-2 infection by vaccination status using Cox regression models.PatientsCYP aged 5–17 with life-limiting neurodisability.ResultsWe identified 38 067 CYP with life-limiting neurodisability; 13 311 (35.0%) received at least one SARS-CoV-2 vaccine, with uptake higher among older, white CYP, from less deprived neighbourhoods. Of 8134 CYP followed up after a positive SARS-CoV-2 test, 1547 (19%) were vaccinated. Within 28 days of infection, 309 (4.7%) unvaccinated CYP were hospitalised with COVID-19 compared with 75 (4.8%) vaccinated CYP. Of 46 (0.7%) unvaccinated CYP were admitted to PICU compared with 10 (0.6%) vaccinated CYP. Of 20 CYP died within 28 days of SARS-CoV-2 infection, of which 13 were unvaccinated. Overall, adjusted hazard of hospitalisation for COVID-19 or admission to PICU did not vary by vaccination status. When the Alpha-Delta SARS-CoV-2 variants were dominant, hazard of hospitalisation with COVID-19 was significantly lower among vaccinated CYP (HR 0.26 (0.09 to 0.74)), with no difference seen during Omicron (HR 1.16 (0.74 to 1.81)).ConclusionsSARS-CoV-2 vaccination was protective of COVID-19 hospitalisation among CYP with life-limiting neurodisability during Alpha-Delta, but not for other SARS-CoV-2 variants. Vaccine uptake was low and varied by ethnicity and deprivation.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

COVID-19 vaccine effectiveness in adults with developmental disabilities living in group homes

Cited by 2 publications

References 5 publications

“They need to speak a language everyone can understand”: Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities

“They need to speak a language everyone can understand”: Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities

COVID-19 vaccine effectiveness and uptake in a national cohort of English children and young people with life-limiting neurodisability

Contact Info

Product

Resources

About